Source comparison
Melanotan-1 vs PT-141: Mechanism Comparison
Primary Receptor Target MC1R (melanocortin-1 receptor on melanocytes) MC4R (melanocortin-4 receptor in hypothalamus) Receptor divergence explains functional difference. Not interchangeable Physiological Outcome Eumelanin synthesis → skin darkening and photopro
This comparison does not assign a generated winner or score.
- Primary Receptor Target
- MC1R (melanocortin-1 receptor on melanocytes)
- MC4R (melanocortin-4 receptor in hypothalamus)
- Receptor divergence explains functional difference. Not interchangeable
- Physiological Outcome
- Eumelanin synthesis → skin darkening and photoprotection
- Dopaminergic/oxytocinergic activation → sexual arousal and desire
- One is peripheral dermatological; the other is central neurological
- FDA-Approved Indication
- Erythropoietic protoporphyria (EPP)
- Hypoactive sexual desire disorder (HSDD) in premenopausal women
- Approved uses reflect distinct therapeutic targets
- Administration Route
- Subcutaneous implant (16 mg every 60 days)
- Subcutaneous injection (1.75 mg as needed) or intranasal spray
- Implant provides sustained release; injection provides acute dosing
- Half-Life
- ~20 hours (from implant. Sustained release over 60 days)
- ~2.7 hours (rapid clearance after subcutaneous injection)
- PT-141's short half-life requires on-demand dosing; Melanotan-1 accumulates
- Common Adverse Events
- Nausea (30%), headache (10%), injection site hyperpigmentation
- Nausea (40%), flushing (20%), injection site reactions (15%)
- Both cause dose-dependent nausea. Mechanism involves MC4R in brainstem